New Triple-Threat treatment trial aims to fight tough lung cancer
NCT ID NCT07318883
Summary
This study is testing whether adding a new antibody called HLX07 to standard immunotherapy and chemotherapy works better for people with advanced squamous non-small cell lung cancer. Researchers will compare different combinations of treatments in 720 participants who haven't had previous treatment for their advanced cancer. The goal is to see if the new combination helps control the cancer longer with fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.